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Cervical cancer screening
K F Tam???? H Y S Ngan???
Summary
In Hong Kong, cervical cancer is the 4th commonest
malignancy in females.  Cervical cytology screening is
effective in reducing the incidence and mortality of
cervical cancer.  Women should have regular cervical
smears from the time they start to have sexual activity until
they reach the age of 65.  A cervical smear should be
taken and handled properly, so that the sensitivity of the
test will not be affected by the quality of the smear.  Most
of the laboratories in Hong Kong are now using the
Bethesda System to report cervical smears.  In order to
manage patients properly, doctors should be familiar with
this classification.
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Introduction
According to the Hong Kong Cancer Registry, there are
about 500 new cases of cervical cancer and 150 deaths from
this disease every year.  Cervical screening programmes have
been running in Hong Kong for many years.  Although there
has been a decrease in age standardised incidence, cervical
cancer remains one of the commonest malignancies in
females.
The existence of a long latency period between the pre-
cancerous stage and invasive cervical cancer formed the basic
justification for cervical cancer screening.  Cervical cytology
screening decreases the incidence and mortality of cervical
cancer.1  Primary care is central to the overall success of the
cervical screening programme.  Family physicians are in a
unique position to invite women for a smear test, to take
smears, to ensure that abnormal smear test results are
followed up, and to check on reasons for non-attendance.2
Who should be screened?
Women are advised to have cervical cytology screening
when they become sexually active until the age of 65.
However, a woman over the age of 65 who has never had a
cervical smear should also be screened.  The age limits for
cervical screening have been a subject of debate.  According
to the recommendation of the Intercollegiate Working Party
in 1997, the cervical screening programme in England and
Wales is targeted at women between 20 and 64 years of age.3
If previous cervical smears have been consistently normal,
women can be discharged from the screening programme
after the age of 65.
Women having risk factors for cervical cancer and who
have not had a cervical smear before, should be encouraged
to have a cervical smear.
Frequency of cervical smear
The reduction in the cumulative incidence of cervical
cancer is 93% with annual or biannual screening interval,
91% if performed every 3 years, 84% if performed every
5 years and 64% if performed every 10 years.  Women having
normal cervical smears on two consecutive years could have
the interval spaced out to 3 years without reducing the chance
of detecting cervical cancer, and at a lower cost.4  However,
in high-risk patients like those who are immunosuppressed
or those who have a history of abnormal cervical smear,
annual screening is advised.
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In the Bethesda System, the term Low-grade Squamous
Intraepithelial Lesion (LSIL) is used to correlate with the
histological diagnosis of Cervical Intraepithelial Neoplasia
(CIN) grade I.  In the presence of human papilloma virus
changes, the smear will still be classified as LSIL even when
no features of intraepithelial neoplasia are seen.  High-grade
Squamous Intraepithelial Lesion (HSIL) correlates with CIN
grade II-III.  Atypical Squamous Cells of Undetermined
Significance (ASCUS) means squamous cell abnormalities
that cannot be accounted for by reactive changes but do not
fulfill the criteria for a specific squamous lesion.  According
to the 1996 Hong Kong colposcopy data, 15% of the patients
having persistent ASCUS have high-grade CIN or even
invasive disease.
Dealing with abnormal cervical smears
An abnormal smear gives a cytological diagnosis.
Cervical intraepithelial neoplasia must then be diagnosed
histologically.  A woman with a cytological screening result
showing a significant chance of having CIN II-III, should be
referred to the colposcopy clinic for assessment.  If a gross
tumour is seen on speculum examination, urgent referral to
a gynaecologist for a biopsy to diagnose cervical cancer
should be advised.  In case of ASCUS or inflammation,
cervical smear should be repeated in 3 to 6 months to allow
for regeneration of cervical epithelium.  If no gross lesion is
seen, please refer to Table 1 and Figure 1 for decision.
Before referring patients to the colposcopy clinic, the
reason for referral should be explained to them in order to
reduce their anxiety.  Some patients might think that they are
suffering from cervical cancer.
The colposcopist will examine the transformation zone
using a colposcope, an instrument incorporating a magnifying
lens.  Application of acetic acid and Lugol’s iodine on to the
cervix help to show up abnormal areas and biopsy will be
taken from these abnormal sites for a histological diagnosis.
The vagina would also be inspected during colposcopic
examination.  Histological confirmation of the colposcopic
diagnosis is advised before embarking on treatment.
Treatment for cervical intraepithelial neoplasia
If a low-grade lesion is confirmed by colposcopy and
biopsy, the patient can be observed because 85% of them will
return to normal in 2 years without treatment, although 15%
Taking a smear
Several methods, such as cervical cytology, cervi-
cography and Human Papilloma Virus (HPV) typing, are used
to screen for cervical cancer.  Cervical cytology remains the
gold standard for cervical cancer screening since this is the
only method with established effectiveness.
The sensitivity of the cervical smear depends greatly on
the quality of the smear.  The presence of inflammatory cells,
blood or debris may affect the quality of the smear.  Smear
should not be taken during menstruation.  If a patient has
pre-existing infection, treatment before taking a cervical
smear is advised.  The broom type device gives a better yield
of endocervical cells than the conventional Ayres’ spatula but
it  is  more expensive.   If  the cervical smear of a
postmenopausal woman is reported to be unsatisfactory,
consider giving oestrogen before repeating another smear.
Cervical cells collected by the spatula should be properly
transferred to the slide.  Too thick a smear especially with
blood or mucus makes interpretation very difficult.  After
being prepared, slides should be fixed immediately using
either a spray fixative or dipping the slide into 95% alcohol.
Liquid based preparations (Thin-prep) are much more
expensive but could reduce the number of unsatisfactory
smears by decreasing the problems mentioned above.5
The cytological examination request form should be
filled in properly.  Patient particulars should be checked
carefully and the slide should be labelled in pencil.  Important
information which may influence the interpretation of the
cervical smear, like the date of last menstrual period,
menopausal status, contraceptive methods, pregnancy, and
history of chemotherapy or radiotherapy should be written
on the request form.
Reporting a smear
Different reporting systems are used for cervical
screening.  In order to ensure proper management of those
women with abnormal cervical smears, it is important to
understand the terminology of smear reports.  A descriptive
report  using unequivocal  terms,  together  with a
recommendation regarding further management, is the type
of report most acceptable to clinicians.
The Bethesda System6 is now the most commonly used
reporting system in Hong Kong and should be used
uniformly.  This classification was first introduced in 1989
by the National Cancer Institute and it was modified in 1992.
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Cervical smear Significance Suggested actions
Normal 0.1% CIN II-III Normal screening programme (once every 3 years after 2 normal
annual smears).
Inflammatory May mask HGSIL or invasive cancer Treat confirmed infection.  Repeat smear in 3-6 months and refer
for colposcopy if abnormality persists.
ASCUS In persistent ASCUS: Repeat smear in 3-6 months.  Refer for colposcopy if abnormality
14% CIN II-III** persists.
0.7% microinvasive
0.2% invasive
Low grade squamous 13.4% CIN II-III* Refer for colposcopy and biopsy.
intraepithelial lesion (LSIL) 0.1% microinvasive
High grade squamous 69.5% CIN II-III* Refer for colposcopy and biopsy.
intraepithelial lesion (HSIL) 2.3% microinvasive
3.5% invasive
Invasive cancer 53.8% microinvasive* or invasive Biopsy if frank growth, otherwise early referral for colposcopy
and biopsy.
Abnormal glandular cells of 17% HG, 5% AIS Refer for colposcopy and biopsy, then cone biopsy and D & C
undetermined significance (AGUS) 2% invasive adenocarcinoma may be required.
Endometrial cells (after menopause) Investigate for endometrial pathology.
at inappropriate time 7% adenocarcinoma
13% hyperplasia
38% endometrial polyp
Table 1: Management of abnormal cervical smear9
* 1996 Hong Kong colposcopy data, some data with colposcopy performed only after persistent ASCUS
** Hong Kong colposcopy data includes persistent ASCUS at second or third smears
(Source: Guidelines on the management of an abnormal smear, The Hong Kong College of Obstetricians and Gynaecologists)
Figure 1: The algorithm in the management of abnormal cervical smear
Cervical smear
Normal Abnormal
Repeat cervical
smear in 1 year
Normal
Cervical smear
every 3 years
ASCUS Inflammation with LSIL Gross tumour
identified infection HSIL
Invasive or
other abnormal smears
Treat the infection
Refer gynaecologist
Repeat smear Repeat smear in for biopsy
in 3-6 months 3-6 months
Normal
Abnormal Refer colposcopy
Repeat cervical smear in 6 months
Normal
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Key messages
1. Women are advised to have cervical smear screening
when they start having sexual activity until the age
of 65.
2. Women having normal cervical smear results in two
consecutive years could have the interval spaced out
to 3 years.
3. Cervical smear should be taken properly.  Cervical
cells collected should be properly transferred to the
slide with immediate fixation.
4. Doctors should be familiar with the Bethesda system
which is the most commonly used reporting system
in Hong Kong.
5. Patients having abnormal cervical smear results
should be informed and properly managed.  They
should have the significance of the results explained
to them, and the reason for referral, if indicated.
randomised controlled trial.2  Women belonging to the
targeted population should be invited to have cervical smears.
A recall system should be available to call patients with
abnormal cervical smears and to remind women who are due
for screening.  Being informed of a normal cytology result
should be reassuring and might make the screening
programme more successful.
Reading materials
Please visit the website (http://www.hkcog.org.hk/
collegeguidelines.htm) of The Hong Kong College of
Obstetricians and Gynaecologists for a full text of the
Guidelines on the Management of An Abnormal Cervical
Smear.     ?
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of them may progress to higher grade lesions.7  However, for
patients who are likely to default further assessment,
treatment can be offered after adequate explanation.
If a high-grade lesion (CIN II/III) is confirmed,
treatment is suggested because a significant proportion will
progress to invasive cancer if left untreated.  The time of
progression to invasive disease can vary from months to
years.  The risk of progression from CIN III to invasive
disease is more than 12%.8
Call-recall system
The effectiveness of a call-recall system in encouraging
women to have a cervical smear has been confirmed by
